Drug intelligence / Profile preview

Hemay183

Development stage: Preclinical
Lead developer: Ganzhou Hemei Pharmaceutical
Modality: Small Molecules

Overview

Hemay183 is an investigational small molecule being developed by Tianjin Hemay Bio-Tech for the treatment of solid tumors. Currently in the preclinical stage of development, the specific molecular target and mechanism of action for Hemay183 remain undisclosed by the company. It represents part of Tianjin Hemay Bio-Tech's oncology pipeline, which focuses on developing novel small molecule therapeutics for various cancer indications.

Beyond the preview

Go deeper on Hemay183.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemay183.

Explore the full profile